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Background: Human pancreatic cancer is currently one of the deadliest cancers with high mortality rate. It has
been previously shown that (−)-epigallocatechin-3-gallate (EGCG), the most abundant catechin found in green tea,
has showed suppressive effects on human pancreatic cancer cells. Bleomycin, (BLM), an anti-cancer
chemotherapeutic drug that induces DNA damage, has antitumor effects by induction of apoptosis in several
cancer cell lines and also in pancreatic cancer cells. The present study investigated for the first time, the inhibitory
effect of EGCG and BLM on pancreatic cancer cell growth.
Methods: Using the pancreatic cancer cell lines MIA PaCa-2 cells the efficacy and synergism of EGCG and BLM
were evaluated by in vitro tests. Inhibition of cell proliferation was determined by MTT assay. Mitochondrial
depolarization was performed with JC-1 probe. Viability and apoptosis were determined by Flow Cytometry with
annexin V, propidium iodide staining and DNA fragmentation assay.
Results: Cell proliferation assay revealed significant additive inhibitory effects with combination of EGCG and BLM
at 72 h in a dose dependent manner. The combination of EGCG and BLM induced cell cycle S-phase arrest and
mitochondrial depolarization. Viability, apoptosis and DNA fragmentation assay indicated that the combination of
EGCG and bleomycin potentiated apoptosis.
Conclusions: Our results indicate that EGCG and BLM have additive anti-proliferative effects in vitro by induction of
apoptosis of MIA PaCa-2 cells. This combination could represent a new strategy with potential advantages for
treatment of pancreatic cancer. To date, this is the first report published of the inhibitory effect of EGCG and BLM
on human pancreatic cancer MIA Paca-2 cell growth.
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Human pancreatic cancer is currently one of the deadliest
cancers with high mortality rate [1]. Only a small fraction
of patients at presentation have resectable disease because
of either presence of distant metastases or locally
advanced disease involving neighboring vasculature and
associated perineural invasion [2]. Radical resection is still* Correspondence: s.bimonte@istitutotumori.na.it
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is generally accepted that a multimodality strategy is
necessary for its management. Conventional treatment
of pancreatic cancer is a combination of surgical resec-
tion, chemotherapy, and radiotherapy [3–5] although
chemotherapeutic agents have not been very effective
for human pancreatic adenocarcinoma. The poor prog-
nosis of pancreatic cancer is due to its tendency for late
presentation, aggressive local invasion, early metastases,
and poor response to chemotherapy. Currently, the best
chemotherapeutic agent available for treatment of pan-
creatic cancer is gemcitabine [6]. However, gemcitabinearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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drug resistance [5]. Thus novel strategies involving
less toxic agents for treatment of pancreatic cancer
have been developed [7–10]. Integrative oncology is a
new focus in cancer research that involves association
of natural compounds, as nontoxic tools, with trad-
itional chemotherapy [11]. The most accepted com-
pounds for chemoprevention in humans are
substances present in diet. It has been showed that
green tea catechins, inhibits tumor growth at different
organ site [12–14]. (−)-Epigallocatechin-3-gallate
(EGCG) is the most abundant catechin found in green
tea and it is used in cancer prevention and treatment.
It has been demonstrated that this compound, is able
to inhibit cell growth and to induce apoptosis in can-
cer cells without normal cellular damage [15, 16].
EGCG also inhibits angiogenesis, possibly through the
inhibition of proangiogenic factors, including vascular
endothelial growth factor (VEGF) [17]. Even if the
chemopreventive activity of EGCG was largely studied,
the underlying mechanisms are not yet completely
clear. Recently, it has been showed that EGCG inhibits
pancreatic cancer orthotopic tumor growth, angiogen-
esis and metastasis associated with inhibition of ERK
and PI3K/AKT pathways and activation of FKHRL1/
FOXO3a [18]. In addition the antiproliferative effects
of EGCG on pancreatic cancer cell growth in vitro, are
potentiated by treatment with pterostilbene, a stilbe-
noid derived from blueberries [11]. Bleomycin (BLM)
is a glycopeptid drug originally isolated from Strepto-
myces verticillus [19, 20] is clinically used for cancer
therapy [20, 21]. The bleomycins are a family of
glycopeptide-derived antitumor antibiotics used clinic-
ally for the treatment of squamous cell carcinomas
and malignant lymphomas [22–24]. Their antitumor
activity is due to selective oxidative cleavage of 5′-
GC-3′ and 5′-GT-3′ sequences in DNA, and possibly
also to RNA oxidative degradation [25–31]. BLM plays
several roles in a network involving multiple pathways for
chromosome remodeling, DNA/RNA binding and pro-
cessing, signal transduction, DNA repair, cell cycle, and
apoptosis [30, 32, 33]. It has been demonstrated that BLM
causes DNA damage and kill HepG2 cells, by apoptosis.
The same effect, it has been observed in PANC-1 and in
HPAC pancreatic cancer cells [34]. Recently, it has been
demonstrated that the anticancer effects of BLM on MIA
PaCa-2 cells is potentiated by electrochemotherapy in
vitro [35]. The present study investigated for the first time,
the inhibitory effect of EGCG and BLM on MIA PaCa-2
pancreatic cancer cell growth. Our results indicate that
EGCG and BLM have additive anti-proliferative effects in
vitro by induction of apoptosis of MIA PaCa-2 cells. This
combination could represent a new strategy with potential
advantages for treatment of pancreatic cancer.Results
Effects of EGCG and BLM on MIA PaCa-2 cell proliferation
We first determined whether EGCG and BLM inhibited
the proliferation of human pancreatic cancer cells by
performing MTT assays on MIA PaCa-2 cells. MTT
assay demonstrated significant reductions in cellular pro-
liferation at all treatments levels after 72 h of incubation
(P = 0.001) (Fig. 1a). This result was also confirmed on
Panc-1 cells (Fig. 1b). We also performed in vitro apop-
tosis assay by flow cytometry, to assess if the combination
treatments enhanced the apoptosis in pancreatic cancer
cells. Our results showed that the percentage of apoptosis
of MIA PaCa-2 cells treated with EGCG (20 μM) and
BLM (20 μM) was higher with respect to controls and to
single treatments (Fig. 2). Taken together, our results
suggest that the combination of EGCG and BLM inhibits
proliferation and enhanced apoptosis of MIA PaCa-2 cells.
Effects of EGCG and BLM on MIA PaCa-2 on cell cycle and
mitochondrial depolarization
We also performed cell cycle analysis of MIA PaCa-2
cells treated with EGCG alone, BLM alone, and both
agents together. Results summarized in Table 1, showed
that normal cell cycle progression was disrupted after
24 h and 48 h of incubation. In particular, treatment
with BLM (20 μM) combined with EGCG (20 μM)
caused an increased percentage of MIA PaCa-2 cells to
arrest in the S-phase compared to controls. We also
tested the mitochondrial depolarization in MIA PaCa-2
cells. Mitochondrial depolarization of JC-1-labeled MIA
PaCa-2 cell was observed after 30 min-treatments.
Results showed that the combination treatment (20 μM
EGCG plus 20 μM BLM) leads to an increase in the per-
centage of depolarized cells (15,2 %) compared to con-
trols (5,00 %) Tables 1 and 2.
Effects of EGCG and BLM on MIA PaCa-2 cells
programmed cell death
To investigate whether cytotoxic effects of BLM were
due to necrosis or apoptosis, we performed an assay of
released nucleosomes. Statistically significant increases
in released nucleosomes when MIA PaCa-2 cells was
treated with BLM (20 μM (110.6 %, 1.646 ± 0.01050) and
EGCG (20 μM) (42.4 %, 1.113 ± 0.0015), and a statisti-
cally significant (P < 0.0001) decrease was observed when
the cells were treated with the combination treatment
(25 %, 0.586 ± 0.017) at 72 h (Fig. 3).
Discussion
The present study investigated for the first time, the
inhibitory effect of EGCG and BLM on human pancre-
atic cancer MiaPaca-2 cell growth. EGCG is the most
widely studied catechin in green tea and has been found
to inhibit the cell cycle and to induce apoptosis [17].
Fig. 1 Effects of EGCG and BLM on MIA PaCa-2 cell proliferation. MTT cell viability assays showing reduction in cellular proliferation from treatment
with EGCG alone, BLM alone, and both agents in MIA PaCa-2 cell lines a and Panc-1 cell lines b in vitro at 48 h of incubation. Data presented as mean ±
standard deviation. ∗P < 0.001, by analysis of variance, compared with control
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sociation with chaperones in pancreatic cancer cell line
Mia Paca-2 [36]. In addition, EGCG has anticancer effect
in human pancreatic carcinoma cells by inhibition of
both focal adhesion kinase and insulin-like growth
factor-I receptor induction of CDK inhibitors, and inhib-
ition of FAK and insulin-like growth factor-1 receptor
[37]. Previous studies have proved the anticancer activity
of EGCG and pterostilbene, including its activation of
caspase-dependent apoptosis in pancreatic cancer [38].
Recent studies revealed that EGCG up-regulated JWA
while decreased topoisomerase IIα expression in both
human non-small cell lung cancer (NSCLC) cells and an
NSCLC xenograft mice model [39]. It has been
demonstrated that in human colorectal cancer cells,
EGCG synergizes the therapeutic effect of cisplatin and
oxaliplatin through autophagic pathway [40]. EGCG is
considered an adjuvant for the treatment of ovariancancer [41]. EGCG has antioxidant activities and re-
solved inflammation during BLM induced pulmonary
fibrosis [42]. BLM is clinically used for cancer therapy
[21]. BLM plays both central and coordinated roles in a
network involving multiple pathways for signal trans-
duction, chromosome remodeling, DNA/RNA binding
and processing, DNA repair, cell cycle, and apoptosis
[30, 32, 33]. The aim of our study was to evaluate the
efficacy and synergism of EGCG and BLM in pancreatic
cancer cells by different in vitro approaches. Our re-
sults indicate that EGCG and BLM have additive anti-
proliferative effects in vitro by induction of apoptosis of
MIA PaCa-2 cells. Additionally, we demonstrated that
these compounds affect mitochondrial depolarization
and cell cycle progression. This combination could rep-
resent a new strategy with potential advantages for
treatment of pancreatic cancer. Although it is important
to work to translate the effective in vitro dosages to
Fig. 2 Effects of EGCG and BLM on MIA PaCa-2 apoptosis. In vitro apoptosis assay by flow cytometry indicated that EGCG and BLM (20 μM)
enhanced apoptosis in MIA PaCa-2 cells (*P value < 0.0001)
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compounds affect the apoptosis and to elucidate the
underlying mechanisms, further studies should be per-
formed. Additional experiments by using different delivery
systems such as microbubbles, nanospheres and cellular
electroporation, will be needed to ameliorate their thera-
peutic effects and in particular to increase cellular
permeabilization of BLM. In the future, we also plan to
study the in vivo effects of EGCG and BLM in orthoto-
pic pancreatic cancer mouse model.Conclusions
Our results indicate that EGCG and BLM have additive
anti-proliferative effects in vitro by induction of apoptosis
of MIA PaCa-2 cells. This combination could represent a
new strategy with potential advantages for treatment of
pancreatic cancer. To date, this is the first report
published of the inhibitory effect of EGCG and BLM on
human pancreatic cancer MIA Paca-2 cell growth.Table 1 Cell cycle analysis with EGCG and BLM in MIA PaCa-2
cells
Treatment G0/G1 S G2/M
MIA PaCa-2
Control 63 12 25
DMSO 64 12 25
20 μM BLM 45 26 27
20 μM EGCG 67 10 22
20 μM EGCG plus 20 μM BLM 50 20 21
Cell cycle analysis MIA PaCa-2 cell lines when treated with EGCG alone, BLM
alone, and both agents togetherMaterials and methods
Cell culture
Human pancreatic cancer cell line MIA PaCa-2 stably
transfected with red fluorescent protein (RPF) and Panc-1
were obtained from the American Type Culture Collection
(ATCC) (Manassas, V, USA). Cells were cultured in RPMI
1640 (Gibco) supplemented with 10 % fetal bovine serum
(FBS; Gibco, Long Island, NY, USA) and 1 % penicillin/
streptomycin (Sigma Aldrich) at in humidified incubators
at 37 °C under an atmosphere of 5 % C02.Proliferation assay
The effect of EGCG and BLM on cell proliferation was
determined by using TACS 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cell prolifera-
tion assay (Trevigen, Githersburg). The cells (2000 per
well) were incubated with EGCG alone, BLM alone or
combination of EGCG and BLM, in triplicate in a 96-Table 2 Mitochondrial depolarization with EGCG and
bleomycin in MIA PaCa-2 cells
Treatment Normal (%) Depolarized(%)
MIA PaCa-2
Positive control 80.8 27.4
DMSO 93.0 4.93
20 μM BLM 91.0 11.3
20 μM EGCG 87.8 13.6
20 μM EGCG plus BLM 80.9 26.2
EGCG = (-)-epigallocatechin-3-gallate; DMSO = dimethyl sulfoxide
Data presented as percentage of normal and depolarized cells
Mitochondrial depolarization of JC-1–labeled MIA PaCa-2 cells after 30-min
treatments
Fig. 3 Effects of EGCG and BLM on MIA PaCa-2 cell death. Cell death detection using enzyme-linked immunosorbent assay at 72 h in MIA PaCa-2
cell lines in vitro when treated with EGCG alone, BLM alone, and both agents together. Data presented as mean ± standard deviation. ∗P < 0.001, by
analysis of variance, compared with control
Bimonte et al. Infectious Agents and Cancer  (2015) 10:22 Page 5 of 7well plate and then incubated for 2, 4 and 6 days at 37 °C.
A MTT solution was added to each well and incubated for
2 h at 37 °C. An extraction buffer (20 % SDS and 50 %
dimethylformamide) was added, and the cells were incu-
bated overnight at 37 °C. The absorbance of the cell sus-
pension was measured at 570 nm using a microplate
reader (DAS Technologies, Chantilly, VA). This experi-
ment was repeated twice, and the statistical analysis was
performed to obtain the final values.
In Vitro apoptosis assay by flow cytometry
Cells were washed and suspended in 0.5 mL of PBS, and
1AL/mL YO-PRO-1, and propidium iodide was added.
Cells were incubated for 30 min on ice and analyzed by
flow cytometry (FACScan, Becton Dickinson, Franklin
Lakes, NJ) by measurements of fluorescence emission at
530 and 575 nm. The apoptotic cells were stained with
the green fluorescent dye YO-PRO-1 while necrotic
cells were stained with propidium iodide. The apoptotic
fraction was obtained by dividing the number of apop-
totic cells by the total number of cells (minimumof 104
cells). Data were analyzed using CellQuest software
(BectonDickinson). All data were reproduced at least
third independent experiments.
Mitochondrial depolarization
Cells were seeded at 3 × 105 cells per well into 6-well
plates and incubated overnight at 37 °C in the carbon di-
oxide incubator; 2 mM of JC-1 (Molecular Probes, Eu-
gene, OR) was added to each well for 20 min at 37 °C.
The cells were then washed with PBS and treated with a
Medium as control or with EGCG (10 μM), EGCG
(20 μM), BLM (10 μM), BLM (20 μM) or the combina-
tions (10 μM EGCG plus 10 μM BLM), (20 μM EGCG
plus 20 μM BLM) for 30 min. The cells were trypsinized,suspended in PBS, and run on the Coulter Elite Flow
Cytometer. The excitation peak of JC-1 is 488 nm, and
the approximate emission peak of the monometric and
J-aggregate forms is 529 and 590 nm, respectively.
Cell cycle analysis
The cells were seeded at 3 × 105 cells per well into 6-well
plates and incubated overnight at 37 °C in the carbon
dioxide incubator. The cells were then washed with PBS
and treated with a Medium as control or with EGCG
(10 μM), EGCG (20 μM), BLM (10 μM), BLM (20 μM)
or the combinations (10 μM EGCG plus 10 μM BLM),
(20 μM EGCG plus 20 μM BLM) for and incubated for
24, 48, or 72 h. The cells were washed with phosphate-
buffered saline (PBS), trypsinized, and incubated in ice-
cold ethanol for 2 h. After incubation, the cells were
washed with PBS and suspended in PBS plus 0.1 %
Triton X-100 plus 100 μg/mL RNase A (Sigma Aldrich)
plus 40 μg/mL propidium iodide (MP Biochemicals,
Salon, OH) for 30 min in the dark. The cells were run
on a Coulter Elite Flow Cytometer. Propidium iodide,
when bound to nucleic acids, has an excitation maximum
at 535 nm and an emission maximum at 617 nm. ModFit
LT, version 3.0, software (Verity Software, Portland, ME)
was used to analyze and categorize cell populations into
cell cycle phases.DNA fragmentation assay
A Cell Death Detection ELISAPLUS Kit (Roche Mannheim,
Germany) was used to detect apoptosis in the cells. It is a
sandwich enzyme immunoassay-based method used to
detect the presence of nuclear DNA fragmentation.
Mouse monoclonal antibodies directed against DNA and
histones were used to recognize released nucleosomes
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seeded into 96-well plates at 104 cells per well and allowed
to incubate at 37 °C in the carbon dioxide incubator for
24 h for the cells to adhere. The cells were then washed
with PBS and treated with a Medium as control or with
EGCG (10 μM), EGCG (20 μM), BLM (10 μM), BLM
(20 μM) or the combinations (10 μM EGCG plus 10 μM
BLM), (20 μM EGCG plus 20 μM BLM) and allowed to
incubate for 48 or 72 h. Lysis buffer was applied to the
adherent cells, and the cells were centrifuged to produce a
nucleosome-containing supernatant. The samples were
transferred to a streptavidin-coated enzyme-linked immu-
noabsorbent assay microplate and incubated with anti-
histone and anti-DNA antibodies. A peroxidase substrate
was applied, causing a subsequent color change, propor-
tional to the amount of nucleosomes captured in the anti-
body sandwich. The plates were read at 405 nm on a
spectrophotometer.
Statistical analysis
Data were analyzed using the Anova Test and expressed
as mean values of at least three independent replications.
Differences were considered to be highly statistically
significant when p <0.01 and significant at p <0.05.
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